| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings Inc. | Zygel (ZYN002) - (RECONNECT) | Fragile X syndrome | Phase 3 | Trial Discontinued | Transdermal | Genetic Disorder |
| Harmony Biosciences Holdings Inc. | WAKIX (Pitolisant HD) - (ONSTRIDE 2) | Idiopathic hypersomnia | Phase 3 | Ongoing | Oral | Neurology |
| Harmony Biosciences Holdings Inc. | ZYN001 | Peripheral Neuropathic Pain (PNP) | Phase 2 | Trial Discontinued | Transdermal | Neurology |
| Harmony Biosciences Holdings Inc. | ZYN001 | Fibromyalgia | Phase 2 | Trial Discontinued | Transdermal | Neurology |
| Harmony Biosciences Holdings Inc. | WAKIX (pitolisant) - (INTUNE) | Idiopathic Hypersomnia (IH) | Phase 3 | Trial Planned | oral | Neurology |
| Harmony Biosciences Holdings Inc. | EPX-100 - (LIGHTHOUSE) | Lennox-Gastaut Syndrome | Phase 3 | Trial Planned | Oral | Neurology |
| Harmony Biosciences Holdings Inc. | EPX-100 - (LIGHTHOUSE) | Lennox-Gastaut Syndrome | Phase 3 | Trial Planned | Oral | Neurology |
| Harmony Biosciences Holdings Inc. | WAKIX (pitolisant) | Type 1 myotonic dystrophy (DM1) | Phase 2 | Data Released | oral | Genetic Disorder |